Intractable diabetic macular edema: A desperate unmet need

June 2013
Ocular Surgery News;6/10/2013, Vol. 31 Issue 11, p24
Academic Journal
The author discusses the management of patients with intractable diabetic macular edema, proposing the consideration of corticosteroid drug delivery devices such as the Ozurdex from Allergan and the Iluvien from Alimera Sciences.


Related Articles

  • First injections can predict anti-VEGF success in DME. Harrison, Laird // Ophthalmology Times;Jan2016, Vol. 41 Issue 1, p29 

    The article reviews research indicating that clinicians can predict a patient's long-term response to anti-vascular endothelial growth factor (VEGF) treatment of diabetic macular edema (DME) after three injections. Topics include researchers Doctor Pravin Dugel and colleagues conducting a post...

  • Baseline subfoveal choroidal thickness portends amount of decrease in fovea, central macula after anti-VEGF treatment.  // Ocular Surgery News;6/10/2014, Vol. 32 Issue 11, p1 

    The article cites presentation at the Association for Research in Vision and Ophthalmology meeting in Orlando, Florida which showed that eyes with thinner baseline subfoveal choroidal thickness decreased faster in foveal thickness and central macular thickness after intravireal anti-VEGF injections.

  • Anti-VEGF treatment improves macular sensitivity in diffuse DME. Hasson, Matt; Hemphill, Nancy; Nhu Te // Ocular Surgery News;6/10/2014, Vol. 32 Issue 11, p17 

    The article cites a poster presentation which stated that anti-VEFG treatment improved macular sensitivity in patients with diffuse diabetic macular edema although not in patients with focal diabetic macular edema.

  • Anti-VEGF patterns of use may vary for DME cases in clinical practice. Harrison, Laird // Ophthalmology Times;Sep2015, Vol. 40 Issue 15, p70 

    The article presents the results of a study on the effectiveness of anti-vascular endothelial growth factor (VEGF) treatments for diabetic macular edema conducted by Dr. Kevin Blinder at Washington University in St. Louis, Missouri. Topics mentioned include disappointing results in clinical...

  • Ranibizumab: In Diabetic Macular Oedema. Frampton, James E. // Drugs;2012, Vol. 72 Issue 4, p509 

    Ranibizumab, an intravitreally administered in-hibitor of vascular endothelial growth factor (VEGF), is approved for the treatment of visual impairment associated with diabetic macular oedema (DME) in the EU. In four well designed, phase II or III trials (RE-SOLVE, RESTORE, RIDE and RISE), 1-2...

  • Combination anti-VEGF, navigated laser for DME on a par with monotherapy. Kernt, Marcus // Ophthalmology Times;Sep2015, Vol. 40 Issue 15, p47 

    The article focuses on the findings of the Early Treatment Diabetic Retinopathy Study on the clinical efficacy of laser photocoagulation in the treatment of diabetic macular edema (DME). Topics mentioned include DME was a leading cause of blindness in developed countries, improved visual acuity...

  • VIVID, VISTA: BCVA better with aflibercept than laser for treatment of DME. Hasson, Matt; Hemphill, Nancy; Nhu Te // Ocular Surgery News;6/10/2014, Vol. 32 Issue 11, p18 

    The article discusses a 2-year subgroup analysis data of the VIVID and VISTA diabetic macular edema (DME) studies which found that intravitreal aflibercept for diabetic macular edema continues to perform better than laser with regard to best corrected visual acuity.

  • Retinal sensitivity in DME improves with anti-VEGF. Biro, Ashley // Ocular Surgery News;3/25/2013, Vol. 31 Issue 6, p43 

    The article reports that aflibercept provides better improvement on retinal sensitivity compared with laser photocoagulation in patients with diabetic macular edema, according to Diana V. Do, a speaker at the Angiogenesis, Exudation, and Degeneration meeting in Miami, Florida on February 9, 2013.

  • MEAD study: Corticosteroid implant improves BCVA at 3 years in eyes with DME. Hasson, Matt // Ocular Surgery News;9/25/2014, Vol. 32 Issue 18, p26 

    The article discusses a study published in an online issue of "Ophthalmology" which compared the effectiveness of corticosteroid implant versus sham treatment in diabetic macular edema (DME). Topics covered include increased intraocular pressure (IOP) and cataract development associated with the...


Read the Article


Sign out of this library

Other Topics